Does clinical method mask significant VTE-related mortality and morbidity in malignant disease?

Maraveyas, A.; Johnson, M.
June 2009
British Journal of Cancer;6/16/2009, Vol. 100 Issue 12, p1837
Academic Journal
After more than 150 years of a recognised link between cancer and vascular thromboembolic events (VTE), and despite a greatly improved understanding of its pathophysiology, epidemiology and treatment, the management of patients with cancer and VTE is still limited. Limitations can be related to the thromboembolism itself, the underlying cancer, or to the management process. There is significant literature that deals with the first two, but very little regarding the systems we use, or how the inadequacies in documentation, identification and classification of VTE affect the cancer patients themselves. This review aims to raise awareness of this neglected area and stimulate research that may lead to improvements in patient care.British Journal of Cancer (2009) 100, 1837–1841; doi:10.1038/sj.bjc.6605091; published online 2 June 2009; www.bjcancer.com


Related Articles

  • Thromboembolic Events in the Cancer Patient. Lin, Julie T. // Journal of Women's Health (15409996);Jul/Aug2003, Vol. 12 Issue 6, p541 

    The article discusses thromboembolic events in the cancer patient. It is major cause of morbidity in cancer patients. These patients develop a hypercoagutable or prothrombotic state, such as thrombocytosis and increased plasma fibrinogen, which results in various malignancy-associated syndromes....

  • Thromboembolism in Cancer Patients: Pathogenesis and Treatment. Adess, Matthew; Eisner, Robert; Nand, Sucha; Godwin, John; Messmore Jr., Harry L.; Wehrmacher, William H. // Clinical & Applied Thrombosis/Hemostasis;Jul2006, Vol. 12 Issue 3, p254 

    In this review we summarize the causes of cancer related thrombosis as well as modern treatment approaches. Malignancy as a risk factor for thromboembolism is becoming increasingly recognized by clinicians caring for these patients. The probability of thrombosis occurring in an individual...

  • Lack of prophylaxis before the onset of acute venous thromboembolism among hospitalized cancer patients: the SWIss Venous ThromboEmbolism Registry (SWIVTER). Kucher, N.; Spirk, D.; Baumgartner, I.; Mazzolai, L.; Korte, W.; Nobel, D.; Banyai, M.; Bounameaux, H. // Annals of Oncology;May2010, Vol. 21 Issue 5, p931 

    Background: Venous thromboembolism (VTE) prophylaxis remains underutilized, particularly in cancer patients. We explored clinical predictors of prophylaxis in hospitalized cancer patients before the onset of acute VTE.

  • Absceso cerebral. Alvis-Miranda, Hernando; José Gutiérrez-Paternina, Juan; Alcalá-Cerra, Gabriel; Milena Castellar-Leones, Sandra; Rafael Moscote-Salazar, Luis // Revista Cubana de Neurología y Neurocirugía;2013, Vol. 3 Issue 2, p162 

    Objective: To review the epidemiology, etiology, physiopathology, diagnosis and the treatment of brain abscess according to the current available evidence. Evidence acquisition: References were identified by PubMed search of last five years publications with English term: "Brain abscess"....

  • Current approaches to the management of osteoporosis in men. Vondracek, Sheryl Follin; Hansen, Laura B. // American Journal of Health-System Pharmacy;9/1/2004, Vol. 61 Issue 17, p1801 

    Purpose. The epidemiology, pathophysiology, diagnosis, and management of osteoporosis in men are reviewed. Summary. Men with osteoporosis account for approximately one fifth of all patients with osteoporosis, and their morbidity and mortality rates from this disease are higher than in other...

  • AF and Venous Thromboembolism - Pathophysiology, Risk Assessment and CHADS-VASc score. Shariff, Nasir; Aleem, Abdul; Singh, Mukesh; Li, Yuan Z.; Smith, Stacey J // JAFIB: Journal of Atrial Fibrillation; 

    Atrial fibrillation (AF) and venous thromboembolism (VTE) are the two most common medical conditions managed with anti-coagulation therapy. Not all the patients with decreased mobility or AF have a similar risk for thromboembolism. The risk factors for venous thromboembolism and thromboemolism...

  • Venous thromboembolic disease and cancer. Fennerty, A. // Postgraduate Medical Journal;Oct2006, Vol. 82 Issue 972, p642 

    Venous thromboembolic disease is a common cause of mortality and morbidity in patients with cancer. Patients have a 5–6-fold increase in the risk for a venous thromboembolism (VTE) compared with the general population, increasing to 6–7-fold for some cancers. Prophylaxis for VTE...

  • Risk of prostate cancer and thrombosis-related factor polymorphisms. GHASEMI, SOMAYEHSADAT; TAVAKOLI, AYDIN; MOGHADAM, MOHAMAD; ZARGAR, MOHAMAD ALI; ABBASPOUR, MARYAM; HATAMNEJADIAN, NASIM; EBRAHIMI, AHMAD // Biomedical Reports;2014, Vol. 2 Issue 1, p53 

    Venous thromboembolism (VTE) is a complication commonly encountered in cancer patients and is considered to be a major cause of morbidity and mortality. The genetic polymorphisms of thrombophilic factors in cancer patients have been focused on during the last few years. However, the number of...

  • Cancer-associated thrombosis: clinical presentation and survival. Amer, Magid H. // Cancer Management & Research;2013, Vol. 5, p165 

    Background: Thromboembolic events are important causes of morbidity and mortality in cancer patients. Clinical presentation in a community-based setting has not been fully clarified. The purpose of this study was to evaluate the incidence, risk factors, role of thrombophilia, and subsequent...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics